Registry following adults with myasthenia gravis receiving routine neurology care
Collects routine care information from people with myasthenia gravis over time.
Plain-language title generated from the registry record
Registry title: PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry
Key facts
- Where
- Waltham, United StatesSee the site
Where in United States
- CorEvitas, LLCWaltham, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CorEvitas
- Trial code
- NCT07217509
- Record updated
- 27 August 2026
- Original description
The design is a prospective, observational (non-interventional) registry for subjects with myasthenia gravis under the care of a neurology provider. Longitudinal data are collected from both subjects and their treating neurology provider during routine clinical encounters using a structured and standardized data collection method. Approximately 1,500 myasthenia gravis subjects with no defined upper limit and 50 clinical neurology sites will be recruited.Read full original descriptionShow less
PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry
The design is a prospective, observational (non-interventional) registry for subjects with myasthenia gravis under the care of a neurology provider. Longitudinal data are collected from both subjects and their treating neurology provider during routine clinical encounters using a structured and standardized data collection method. Approximately 1,500 myasthenia gravis subjects with no defined upper limit and 50 clinical neurology sites will be recruited.
Inclusion: To be eligible to participate in this registry, an individual must meet all the following criteria:; Has been diagnosed with myasthenia gravis by a neurologist or a qualified neurology practitioner; Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment; Willing and able to provide informed consent; Willing and able to provide Personally Identifiable Information (full legal name, sex at birth, date of birth, home address zip/postal code and email address or phone Number at a minimum) if required based on registry location and applicable laws and regulations; In addition, subject must meet at least one of the criteria:; Have started taking a new Enrollment Eligible Medication within 12 months prior to the Enrollment visit. A new medication is a medication that the subject has never taken before; OR; Is initiating (prescribed or starting) a new Enrollment Eligible Medication at the Enrollment visit. A new medication is a medication that the subject has never taken before.
Exclusion: An individual who meets any of the following criteria will be excluded from participation in the registry:; Is participating or planning to participate in a double-blind clinical trial for a myasthenia gravis drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.